Nutritional supplement: NADH to possibly treat Alzheimer's and Chronic Fatigue Syndrome

NADH, a naturally-occurring coenzyme, shows promise in increasing cognitive function and energy levels.


| November/December 1997



11-97-067-son.jpg


NADH shows promisefor Parkinson’s, CFS, Alzheimer’s 

Preliminary research on NADH, a coenzyme found in all living cells, shows that it may help treat some degenerative diseases and chronic fatigue syndrome.

Building on studies conducted by European researcher Dr. Georg Birkmayer, researchers at Georgetown University Medical Center began two double-blind human trials in 1996 testing Birkmayer’s patented form of NADH (nicotinamide adenine dinucleotide), marketed as Enada. The Georgetown trials focus on Alzheimer’s disease and chronic fatigue syndrome (cfs) and, so far, are encouraging, according to a Georgetown press release. Study results could be complete by late 1997 and 1998.

The trials have been approved by the U.S. Food and Drug Administration (FDA) through the Investigational New Drug process, which allows the FDA to stop trials of promising but unknown drugs if they appear to be dangerous to human health, according to Arthur Whitmore, an FDA spokesman. The process doesn’t indicate FDA approval of Enada’s use as a drug.

The research behind NADH

Georg Birkmayer, a medical doctor who has studied NADH since the mid-1980s, has published the results of many of his pilot studies on NADH. Birkmayer is director of the Birkmayer Institute for Parkinson Ther­apy in Vienna, Austria, and of the neurochemistry division at the University of Graz, Austria. He also is the secretary general of the International Academy of Tumor Marker Oncology and the European editor of the Journal of Tumor Marker Oncology.

During the early 1960s, Georg Birkmayer’s father, Waltham Birkmayer, researched L-dopa as a treatment for Parkinson’s disease. L-dopa is sold as the drug Sinemet, but it isn’t effective for all Parkinson’s patients after long-term use.

Because of that, the Birkmayers tested NADH on 470 Parkinson’s patients. According to their published research, the treatment improved symptoms for the study participants. The Birkmayers subsequently developed Enada, a stabilized, enteric-coated form of NADH that can be taken orally.





mother earth news fair

MOTHER EARTH NEWS FAIR

Oct. 21-22, 2017
Topeka, KS.

More than 150 workshops, great deals from more than 200 exhibitors, off-stage demos, inspirational keynotes, and great food!

LEARN MORE